Search Hotels in Sausalito

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

January 07, 2026

From Exelixis, Inc.

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

January 05, 2026

Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology

January 05, 2026

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...

Via MarketMinute

3 Growth Stocks with Explosive Upside

December 28, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Over the past six months, Natera has been a great trade, beating the S&P 500 by 24.2%. Its stock price has climbed to $235.65, representing a healthy 37.1% increase. This was partly thanks to its solid...

Topics Energy

3 Reasons We’re Fans of Natera (NTRA)

December 23, 2025

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the...

Topics Stocks

3 Market-Beating Stocks Worth Your Attention

December 22, 2025

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 22, 2025

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

December 18, 2025

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

December 16, 2025

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

December 12, 2025

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

December 10, 2025

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

December 09, 2025

Natera Acquires Foresight Diagnostics

December 05, 2025

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

December 03, 2025

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

December 02, 2025

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.

3 Cash-Producing Stocks with Solid Fundamentals

December 01, 2025

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗

November 30, 2025

Stanley Druckenmiller is considered one of the greatest investors of all time.

Via The Motley Fool

Topics Artificial Intelligence

Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know

November 24, 2025

A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.

Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

Topics Economy Government

November 23, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.

Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know

Topics Artificial Intelligence

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the...

Topics Economy

Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3

November 19, 2025

Topics Artificial Intelligence

Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month

November 19, 2025

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

Natera Integrates with Flatiron Health’s OncoEMR® Platform

November 12, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the...

1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds

November 11, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Topics Stocks

2 Surging Stocks with Impressive Fundamentals and 1 We Question

November 10, 2025